RxDoctor Payments Data

Marilou Patalinjug Tyner, MD

Psychiatry · Nashua, NHNPI 1811901689

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 44.2% of the total. Reporting peaked in 2021 at $152 and has fallen 52.7% since, to $72 in 2025.

$650in general payments, 2019–2025

Across 27 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$287
  • E.r. Squibb & Sons, L.L.C.$147
  • Alkermes, Inc.$118
  • Johnson & Johnson$66
  • Neurocrine Biosciences, Inc.$32

What the payments were for

  • Food & beverage$62095%
  • Education$305%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$650 in reported general payments places this provider in the 70th percentile of 166 psychiatry providers in New Hampshire.

See all psychiatry providers in New Hampshire

Medicare billing

Part B allowed, 2024
$267,232
Medicare patients
300
Services billed
2,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate173$542,216
Abilify MaintenaAripiprazole101$253,894
IngrezzaValbenazine Tosylate27$219,576
Invega TrinzaPaliperidone Palmitate21$194,061
LybalviOlanzapine/Samidorphan Malate58$87,702
RexultiBrexpiprazole30$41,885
Paliperidone ErPaliperidone130$32,943
Clozapine330$23,086
Chlorpromazine Hcl30$22,312
Lurasidone Hcl59$15,234
VraylarCariprazine Hcl11$14,773
Divalproex Sodium ErDivalproex Sodium263$13,886
Fluphenazine Hcl51$9,646
Quetiapine Fumarate513$9,194
Aripiprazole182$7,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Invega$66$743,233207 claims
Neurocrine Biosciences, Inc.Ingrezza$32$219,57627 claims
Alkermes, Inc.Lybalvi$118$87,70258 claims
AbbVieVraylar$287$14,77311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 166 psychiatry providers in New Hampshire.

Other psychiatry in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →